<?xml version="1.0" encoding="UTF-8"?>
<p id="par0210">Nitazoxanide (
 <bold>89</bold>, 
 <xref rid="fig0065" ref-type="fig">Fig. 13</xref> ) is another potent type I interferon inducer that has been used in humans for parasitic infections 
 <xref rid="bib0660" ref-type="bibr">[132]</xref>. A synthetic nitrothiazolylâ€“salicylamide derivative exhibits broad-spectrum antiviral activities against both RNA and DNA viruses including canine CoV, influenza viruses, HBV, HCV, HIV, rotavirus, norovirus, and flaviviruses 
 <xref rid="bib0660" ref-type="bibr">[132]</xref>. It has been evaluated in Phase II and Phase III clinical trials for the treatment of HCV infection and influenza and has a good safety profile 
 <xref rid="bib0660" ref-type="bibr">132</xref>, 
 <xref rid="bib0700" ref-type="bibr">140</xref>, 
 <xref rid="bib0705" ref-type="bibr">141</xref>.
</p>
